Evidence map›Paper›PMID 40309507›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Biosafety status analysis and risk assessment of laboratories from 2021 to 2023 in Jiaxing, China.

Yong Yan, Chan Li, Jingyu Xu, Lei Gao, Zhenggang Jiang, Shencong Lv, Ping Li, Zelin Xiang, Peiyan He, Ganglin Ren and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yong Yan *Jiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Chan Li *Department of Research and Emergency, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
Jingyu Xu *Department of Microbiology, Haiyan Center for Disease Control and Prevention, Haiyan, Zhejiang, China.
Lei GaoJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Zhenggang JiangDepartment of Research and Emergency, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
Shencong LvJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Ping LiJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Zelin XiangJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Peiyan HeJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Ganglin RenJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Guoying ZhuJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.
Zhongwen ChenJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to understand the laboratory biosafety status of Jiaxing from 2021 to 2023, before and after the end of the COVID-19 strict control strategy, this study used Zhejiang local standard DB33/T 2540 to conduct biosafety quality control inspection and risk identification, and used Chinese industry standard RB/T 040 for risk analysis and assessment. The results showed that the major problems in biosafety management were from organization management, laboratory housekeeping, material and label management, and facilities and equipment, accounting for 39.76%, 28.97% and 14.69% respectively. Statistical analysis showed that the significant improvement of laboratory filing requirements (

Indexed as

biosafetybiosecuritylaboratorypublic healthquality controlrisk assessment

Identifiers

PMID40309507
PMCPMC12040964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.